https://www.selleckchem.com/products/OSI-906.html
After PS-matching (n=174 in each group), no significant difference in ICU mortality was observed (controls 32% vs. SB-group 41%; p=.07). Odds ratios (OR) for ATE and ATT showed no association with ICU mortality (OR ATE 1.08, 95%-CI 0.99-1.17; p=.08; OR ATT 1.09; 95%-CI 0.99-1.2; p=.09). Hazard ratios at 20-days (multivariable HR, matched sample n=348 1.16, 95%-CI 0.86-1.56, p=.33) showed similar survival in the two study groups. We did not observe effects of SB infusion on all-cause mortality in critically ill patients with metabolic ac
Like
Comment
Share
